Pseudoprogression and Immune-Related Response in Solid Tumors

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2015 Aug 12

PMID 26261262

Citations 424

Authors

Victoria L Chiou

Mauricio Burotto

Affiliations

Soon will be listed here.

Citing Articles

Evaluation of surrogate endpoints in phase III randomized control trials of advanced hepatocellular carcinoma treated with immune checkpoint inhibitors.

Jiang K, Liu M, Zhao X, Wang S, Ling Y, Qiao L Eur J Clin Pharmacol. 2025; .

PMID: 40080137 DOI: 10.1007/s00228-025-03820-y.

Hyperprogression of brain metastases following initiation of immune checkpoint inhibitors.

Jessurun C, Siddi F, Nawabi N, Hulsbergen A, Lo Y, Jha R J Neurooncol. 2025; .

PMID: 39918777 DOI: 10.1007/s11060-025-04955-9.

Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial.

Pakola S, Clubb J, Kudling T, van der Heijden M, Jirovec E, Arias V J Immunother Cancer. 2025; 13(1).

PMID: 39870491 PMC: 11772932. DOI: 10.1136/jitc-2024-010493.

Multiparametric MRI and artificial intelligence in predicting and monitoring treatment response in bladder cancer.

Arita Y, Kwee T, Akin O, Shigeta K, Paudyal R, Roest C Insights Imaging. 2025; 16(1):7.

PMID: 39747744 PMC: 11695553. DOI: 10.1186/s13244-024-01884-5.

High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC.

Altan M, Li R, Li Z, Chen R, Sheshadri A, Tran H J Immunother Cancer. 2024; 12(12).

PMID: 39721752 PMC: 11683914. DOI: 10.1136/jitc-2024-008950.

References

Wolchok J, Kluger H, Callahan M, Postow M, Rizvi N, Lesokhin A . Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369(2):122-33. PMC: 5698004. DOI: 10.1056/NEJMoa1302369. View

Motzer R, Rini B, Mcdermott D, Redman B, Kuzel T, Harrison M . Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol. 2014; 33(13):1430-7. PMC: 4806782. DOI: 10.1200/JCO.2014.59.0703. View

Fojo A, Noonan A . Why RECIST works and why it should stay--counterpoint. Cancer Res. 2012; 72(20):5151-7. DOI: 10.1158/0008-5472.CAN-12-0733. View

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-64. PMC: 4856023. DOI: 10.1038/nrc3239. View

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

Brahmer J, Drake C, Wollner I, Powderly J, Picus J, Sharfman W . Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010; 28(19):3167-75. PMC: 4834717. DOI: 10.1200/JCO.2009.26.7609. View

Wolchok J, Hoos A, ODay S, Weber J, Hamid O, Lebbe C . Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15(23):7412-20. DOI: 10.1158/1078-0432.CCR-09-1624. View

10.

Di Giacomo A, Danielli R, Guidoboni M, Calabro L, Carlucci D, Miracco C . Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother. 2009; 58(8):1297-306. PMC: 11030873. DOI: 10.1007/s00262-008-0642-y. View

11.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

12.

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

13.

Herbst R, Soria J, Kowanetz M, Fine G, Hamid O, Gordon M . Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515(7528):563-7. PMC: 4836193. DOI: 10.1038/nature14011. View

14.

Powles T, Eder J, Fine G, Braiteh F, Loriot Y, Cruz C . MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014; 515(7528):558-62. DOI: 10.1038/nature13904. View

15.

Robert C, Ribas A, Wolchok J, Hodi F, Hamid O, Kefford R . Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014; 384(9948):1109-17. DOI: 10.1016/S0140-6736(14)60958-2. View

16.

Rizvi N, Mazieres J, Planchard D, Stinchcombe T, Dy G, Antonia S . Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015; 16(3):257-65. PMC: 5726228. DOI: 10.1016/S1470-2045(15)70054-9. View

17.

Weber J, DAngelo S, Minor D, Hodi F, Gutzmer R, Neyns B . Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015; 16(4):375-84. DOI: 10.1016/S1470-2045(15)70076-8. View

18.

Weber J, Kudchadkar R, Yu B, Gallenstein D, Horak C, Inzunza H . Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013; 31(34):4311-8. PMC: 3837092. DOI: 10.1200/JCO.2013.51.4802. View

19.

Topalian S, Sznol M, Mcdermott D, Kluger H, Carvajal R, Sharfman W . Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014; 32(10):1020-30. PMC: 4811023. DOI: 10.1200/JCO.2013.53.0105. View

20.

Hamid O, Robert C, Daud A, Hodi F, Hwu W, Kefford R . Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013; 369(2):134-44. PMC: 4126516. DOI: 10.1056/NEJMoa1305133. View